Check for updates

#### **OPEN ACCESS**

EDITED BY Sunjoo Kang, Yonsei University, South Korea

#### REVIEWED BY

Deborah L. Billings, University of South Carolina, United States Salvatore Giovanni Vitale, University of Messina, Italy

\*CORRESPONDENCE Natnael Atnafu Gebeyehu jossyatnafu2020@gmail.com

#### SPECIALTY SECTION

This article was submitted to Public Health Education and Promotion, a section of the journal Frontiers in Public Health

RECEIVED 27 June 2022 ACCEPTED 21 November 2022 PUBLISHED 06 December 2022

#### CITATION

Gebeyehu NA, Tegegne KD, Biset G, Sewuyew DA, Alemu BW and Yitayew AM (2022) Discontinuation of long acting reversible contraceptive use and its determinants among women in Ethiopia: Systematic review and meta-analysis. *Front. Public Health* 10:979231. doi: 10.3389/fpubh.2022.979231

#### COPYRIGHT

© 2022 Gebeyehu, Tegegne, Biset, Sewuyew, Alemu and Yitayew. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).

The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Discontinuation of long acting reversible contraceptive use and its determinants among women in Ethiopia: Systematic review and meta-analysis

Natnael Atnafu Gebeyehu<sup>1\*</sup>, Kirubel Dagnaw Tegegne<sup>2</sup>, Gebyaw Biset<sup>3</sup>, Dagne Addisu Sewuyew<sup>4</sup>, Biresaw Wassihun Alemu<sup>5</sup> and Alemker Mola Yitayew<sup>6</sup>

<sup>1</sup>Department of Midwifery, College of Medicine and Health Science, Wolaita Sodo University, Sodo, Ethiopia, <sup>2</sup>Department of Comprehensive Nursing, College of Medicine and Health Science, Wollo University, Dessie, Ethiopia, <sup>3</sup>Department of Pediatrics and Child Health Nursing, College of Medicine and Health Science, Wollo University, Dessie, Ethiopia, <sup>4</sup>Department of Midwifery, College of Medicine and Health Science, Debretabore University, Debre Tabor, Ethiopia, <sup>5</sup>Department of Midwifery, College of Medicine and Health Science, Injbara University, Injbara, Ethiopia, <sup>6</sup>School of Medicine, College of Medicine and Health Science, Wolaita Sodo University, Wolaita, Ethiopia

**Introduction:** Contraception discontinuation is a major public health issue that leads to unwanted pregnancies and unsafe abortions. Therefore, this systematic review and meta-analysis aimed to estimate discontinuation of contraceptives and its determinants in Ethiopia.

**Methods:** PubMed, Google Scholar, Scopus, Science Direct, and Addis Ababa University online library were searched. Data were extracted using Microsoft Excel and analyzed using STATA statistical software (v. 14). Publication bias was checked by forest plot, Begg's rank test, and Egger's regression test. To look for heterogeneity, I<sup>2</sup> was computed, and an overall estimated analysis was carried out. Subgroup analysis was done by region, study setting, and publication. The pooled odds ratio for associated factors was also computed.

**Results:** Out of 654 studies assessed, 20 met our criteria and were included in the study. The total number of study participants was 8,780. The pooled prevalence of discontinuation of long acting reversible contraceptive use was 36.94% (95% CI: 28.547–45.326). According to sub-group analysis, Amhara region (45%) and institution-based studies (47.9%) had the highest prevalence. The most common reason for contraceptive discontinuation was negative side effect (42.3%).

Women experienced side effects (AOR = 2.833:95% CI:2.005-4.003), didn't receive counseling on side effects (AOR = 2.417; 95% CI: 1.591-3.672), didn't appoint follow up (AOR = 2.820; 95% CI: 2.048-3.881), dissatisfied with the given service (AOR = 5.156; 95% CI: 3.644-7.296), and a desire to be pregnant (AOR = 2.366; 95% CI: 1.760-3.182) were predictors of discontinuation of contraceptives.

**Conclusion:** In Ethiopia, the pooled prevalence of long acting contraceptive discontinuation was high. Side effects, not being informed about side effects, dissatisfaction with the provided service, no insertion follow-up, and a desire to become pregnant were all associated factors. Healthcare professionals should

focus on the client's reproductive goals, proper management of side effects, counseling, and post-insertion visits.

**Systematic review registration:** https://www.crd.york.ac.uk/prospero/ display\_record.php?ID=CRD42022347860, identifier CRD42022347860.

#### KEYWORDS

contraceptive device, contraceptive agents, birth control, long acting, family planning, discontinuation, long acting contraceptive, Ethiopia

## Introduction

Reduced maternal mortality and universal access to reproductive health care are both improved by family planning (1, 2). As a result, it contributes to a 44% reduction in maternal mortality and a 21% reduction in deaths among children under the age of five (3). Long-acting reversible contraceptives include copper intrauterine devices and hormonal implants (4). In the world, 15% of women use long-acting reversible contraception (5). However, just 3% of women in Sub-Saharan Africa use long acting reversible contraception on a regular basis (6).

Even though the use of long-acting reversible contraception is improving, discontinuation is becoming to be a serious issue. Within a year of insertion, 20% of women in lowincome countries discontinue using long acting reversible contraceptive methods (7). When women who "begin a contraceptive technique and cease it for any reason while still at risk of becoming pregnant," this is known as contraceptive discontinuation (8). Contraception use, fertility, unexpected pregnancies, induced abortions, and miscarriages are all affected (9–11).

There has been a noticeable shift from an emphasis on "adopters" to a concern over "discontinuers" in the predictors of contraceptive ever-use across strategies, as per earlier studies (8, 12). Family planning programs would therefore be better off focusing on maintaining current users than on attracting new ones in order to avoid contraceptive discontinuation. Discontinuation can occur for a number of reasons, but the most common one is side effects that arise while in an emergency (8).

In Ethiopia, providing a long-acting form of family planning is a free but highly effective method of preventing unintended pregnancies (13). Cramping and changes in bleeding patterns are commonly reported as reasons for removal of the intrauterine uterine device and implant, with 6–17% of long-acting reversible contraceptive discontinuation occurring between 6 and 12 months (14).

Long-acting contraceptives are discontinued, which leads to unintended pregnancy, unwanted births, and abortion, all of which are detrimental to women's health. Every year, one-third of the 182 million pregnancies worldwide are unplanned, resulting in larger families, higher fertility, and social, economic, and physical problems (15). Evidence showed that after 3 months of use, 40% of women in Egypt, 51% in Kenya, 73% in Malawi, 56% in United Republic of Tanzania, and 47% in Zimbabwe were at risk of conception (10). By 3 years of use, 45% of intrauterine devices and 61% of implants had been discontinued in Ethiopia (16).

The primary goal of contraception is to avoid unwanted or untimely pregnancies (17). As a result, effective contraception might save 54 million unintended pregnancies, 79,000 maternal deaths, and one million baby deaths per year (18). In contrast, Ethiopia has one of the world's highest maternal death rates, with 412 per 100,000 live births (19). To address this, Ethiopia's Minister of Health outsourced long-acting family planning services to Health Extension Workers at the health post level (20).

Despite the fact that various primary studies have documented the proportion of long-acting contraceptive discontinuation in Ethiopia, there is no data at the country level. Therefore, the purpose of this systematic review and meta-analysis was to estimate the proportion of discontinued of long acting contraceptives and associated factors in Ethiopia. The results of this study will give family planning providers and other stakeholders the fundamental information they need to assist and manage women's discontinuation of long acting reversible contraception.

#### Methods

#### Reporting

This systematic review and meta-analysis study was conducted to determine cause, magnitude and its determinant of discontinuation of long acting reversible contraceptives in Ethiopia using the standard PRISMA checklist guideline (21) (Additional file 1). The review protocol was registered with the international prospective register of systematic review (PROSPERO) as number CRD42022347860.

#### Search strategy

International online databases (Pub Med, Science Direct, Scopus, and Google Scholar) were used to search articles on the prevalence of discontinuation of long acting reversible contraceptives and determinant's. We also retrieved gray literature from Addis Ababa University's online research institutional repository. The search string was established using "AND" and "OR" Boolean operators. The following core search terms and phrases with Boolean operators were used to search related articles: ((((Discontinuation) OR ("Discontinuation" OR "Early removal")) AND Long acting contraception) OR ("Long acting contraception" OR "Implants" OR "Implanon" OR "Jadelle" OR "Intrauterine contraceptive device" OR "Contraceptive" OR "Family planning" OR "Contraceptive device" OR "Contraceptive agent" OsR "Birth control device")) AND Ethiopia. Search terms were based on PICO principles to retrieve relevant articles through the databases mentioned above. The search period covered studies conducted from 2010 to 2021 and published from 2015 to 2022 from April 1, 2022, to May 10, 2022.

#### Outcome measurement

#### Long acting reversible contraceptive methods

Contraceptive methods which serve as 3–10 years but can be removed at any time; only implants and IUCD (22).

# Discontinuation of long-acting reversible contraceptives

Initiating nd stopping long-acting reversible contraceptives before the end of the prescribed period due to a method difficulty (23).

#### Inclusion and exclusion criteria

Only English language papers, including published and unpublished studies with full text available for search, and studies that took place in Ethiopia were included in this metaanalysis. This systematic review and meta-analysis excluded research that used duplicated sources, qualitative studies from developed nations, and articles without full text.

#### Quality assessment

Two authors (NAG and KDT) independently appraised the standard of the studies using the Joanna Briggs Institute (JBI) standardized quality appraisal checklist (24). The disagreement raised during the quality assessment was resolved through a discussion led by the third author (BWA). Finally, the argument was solved and reached with an agreement. The critical analysis checklist has eight parameters with yes, no, unclear, and not applicable options. The parameters involve the following questions:

- (1) Where were the criteria for inclusion in the sample clearly defined?
- (2) Were the study subjects and, therefore, the setting described in detail?
- (3) Was the exposure measured result validly and reliably?
- (4) Were the main objective and standard criteria used to measure the event?
- (5) Were confounding factors identified?
- (6) Were strategies to affect confounding factors stated?
- (7) Were the results measured indeed and dependably? and
- (8) Was the statistical analysis suitable?. Studies were considered low risk when they scored 50% and above on the quality assessment indicators, as reported in Additional File 2.

#### Risk of bias assessment

Two authors (NAG and BWA) independently assessed included studies for risk of bias through the bias assessment tool developed by Hoy et al. (25), consisting of ten items that assess four domains of bias and internal and external validity. Any disagreement raised during the risk of bias assessment was resolved through a discussion led by DS. Finally, the argument was solved and reached with an agreement. The first four items (items 1-4) evaluate the presence of selection bias, non-response bias, and external validity. The other six items (items 5-10) assess the presence of measuring the bias, analysis-related bias, and internal validity. Therefore, studies that received "yes" for eight or more of the ten questions were classified as "low risk of bias." If studies that received "yes" for six to seven of the ten questions were classified as "moderate risk" whereas studies that received "yes" for five or fewer of the ten questions were classified as 'high risk' as reported in a Additional File 3.

#### Data extraction

Microsoft Excel spreadsheet (2016) and STATA version 14 software were utilized for data extraction and analysis. Two authors (NAG and KDT) independently extracted all relevant data using a standardized Joanna Briggs Institute data extraction format. The disagreement raised during data extraction was resolved through a discussion led by the BA. Finally, the argument was solved and reached with an agreement. The data automation tool was not used due to this study's absence of the paper form (manual data). The name of the first author,



year of publication, study region, study setting, study design, the prevalence of knowledge, attitude, practice, sample size, and quality of each paper was extracted.

#### Data analysis

After extracting all relevant findings in a micro-soft excel spreadsheet, the data were exported to STATA software version 14 for analysis. The pooled prevalence of unintended pregnancy was computed using a 95% confidence interval. Publication bias was checked by funnel plot and more objectively through Begg and Egger's regression tests, with P < 0.05 indicating potential publication bias. The presence of between-study heterogeneity was checked by using the Cochrane Q statistic. This heterogeneity between studies was quantified using  $I^2$ , in which a value of 0, 25, 50, and 75% represented no, low, medium, and high heterogeneity, respectively. A forest plot was used to visually assess the presence of heterogeneity, which presented at a high-level random-effect model was used for analysis to estimate the overall prevalence of knowledge, attitude, and practice of exclusive breastfeeding. Subgroup analysis was done

by study setting, study design, study region, year of insertion and cause of discontinuation. Sensitivity analysis was executed to see the effect of a single study on the overall prevalence of the metaanalysis estimate. The findings of the study were presented in the form of text, tables, and figures.

## Results

#### Search findings and study characteristics

Through online search engines such as PubMed, Scopus, Google Scholar, Science direct, and online research repository home, 654 articles were found using a search strategy on discontinuation of long acting reversible contraceptive methods in Ethiopia. There were 503 studies left after duplicates were deleted. After then, the remaining 503 studies were evaluated based on their entire titles and abstracts. As a result, 156 full-text articles were assessed for eligibility criteria, with 136 studies being excluded due to various factors. Finally, for this systematic review and meta-analysis study, 20 publications (23, 26–44) were used as presented by PRISMA diagram (Figure 1).

References	Region	Study setting	Study design	Sample size	Cause	Prevalence	e quality
Dagnew et al. (26)	Amhara	Institutional	cross-sectional	527	NR	37	Low-risk
Nageso and Gebretsadik	SNNPR	Community	Cross-sectional	683	Side effect	23.4	Low- risk
(27)							
Siyoum et al. (27)	Amhara	Community	Cross-sectional	314	Menstrual problem	40.5	Low- risk
Wondie et al. (29)	Amhara	Community	Cross-sectional	312	Side effect	16.7	Low -risk
Melkamu et al. (30)	Amhara	Institutional	Cross-sectional	499	Side effect	65	Low-risk
Weldekidan et al. (31)	SNNPR	Community	Cross-sectional	222	Menstrual problem	22.5	Low-risk
Gaenamo (32)	SNNPR	Institutional	Cohort	473	Desire of pregnancy	38.4	Low-risk
Abebe et al. (23)	SNNPR	Institutional	Cross-sectional	442	Menstrual problem	56.6	Low-risk
Obsu et al. (33)	Oromia	Commuity	Cross-sectional	360	Side effect	42	Low-risk
Mesha et al. (34)	SNNPR	Community	Cross-sectional	430	NR	34	Low-risk
Habte et al. (35)	SNNPR	Institutional	Cohort	502	Side effect	40.5	Low-risk
Amare and Reda (36)	SNNPR	institutional	Cross-sectional	351	Menstrual problem	49.3	Low-risk
Nega et al. (37)	SNNPR	Community	Cross-sectional	475	Side effect	23.2	Low-risk
Tesfaye et al. (38)	Oromia	Community	Cross-sectional	430	NR	19.3	Low-risk
Geja et al. (39)	SNNPR	Community	Cross-sectional	429	Desire of pregnancy	22.4	Low-risk
Tolesa et al. (44)	SNNPR	Institution	Cross-sectional	1,050	Side effect	69.8	Low-risk
Abraha et al. (40)	Tigray	Institutional	Cohort	413	Side effect	18.2	Low –risk
Gebrekidan et al. (42)	Tigray	Institutional	Cross-sectional	229	Desire of pregnancy	38	Low-risk
Birhane (43)	Tigray	Community	Cross-sectional	224	Health concern	16	Low-risk
Yilkal (41)	Amhara	Institutional	Cross-sectional	415	Side effect	66	Low-risk

TABLE 1 Characteristics of the included studies in the systematic review and meta-analysis for the prevalence of discontinuation long acting reversible contraception in Ethiopia 2022.

The cross-sectional study type was used in seventeen studies, whereas the retrospective cohort study approach was used in three. Both community and institutional studies were equally represented (10 studies in each). Nine studies conducted in Southern Nations Nationalists and Peoples Region (23, 27, 31, 32, 34–37, 39), five in Amhara (26, 28–30, 41), three in Tigray (40, 42, 43), and three in Oromia (33, 38, 44). The sample sizes ranged from 222 to 1050. The prevalence of discontinued of long acting contraceptive method ranged from 16 to 69.8. All of the studies were evaluated using the Joanna Briggs Institute (JBI) quality appraisal checklist, and all of them were found to be low risk (Table 1).

#### Meta-analysis

# Prevalence of discontinuation of long acting contraceptive methods in Ethiopia

The overall burden of discontinuation of long acting contraceptives method is presented with a forest plot (Figure 2). Therefore, the national pooled estimate of discontinuation of long acting contraceptive methods in Ethiopia was 36.94% (95% CI: 28.547–45.326;  $I^2 = 98.7\%$ , P < 0.001).

#### Sub-group analysis

The sub-group analysis was done based on study region, setting, cause of discontinuation, year of insertion and study design. The Amhara region had the highest rate of discontinuation of long-acting contraceptive methods (45%), whereas Oromia region had the lowest rate (30.6%). Institutional studies (47.9%) found a greater rate of long-acting contraceptive methods discontinuation than community-based research (25.9%). In terms of study design, cross-sectional studies (37.7%) revealed a higher rate of long-acting family planning method discontinuation than cohort studies (32.3%). On the other hand, side effects were cited as a main reason for the discontinuation of long-acting family planning methods (42.3%). Within three years, the highest rate of discontinuation of long-acting contraceptive methods (48.9%) was found (Table 2).

#### Leave-one-out-sensitivity analysis

A leave-one-out sensitivity analysis was carried out to detect the effect of each study on the overall prevalence of discontinuation of long acting contraceptive methods by

Author/year	<sup>%</sup> ES (95% CI) Weight
Gizachew Worku et.al/2021 Negso and Gebretsadik et.al/2018 Melese Siyoum et.al/2017 Awoke Geltaw Woldie et.al/2019 Mengistu Melkamu et.al/2018 Haregwa Asnake/un-pub Gaenamo AA/2021 Abebe et.al/2020 Obsu et.al/2022 Mamecha Mesha et.al/2020 Habtie et.al/2021 Abebe and Terefe /2020 Nega et.al/2021 Geja et.al/2021 Geja et.al/2021 Bereku et.al/2022 Abreha et.al/2022 Gebremedihn et.al/2019 Kalayu Birhan et.al/2015 Yilkal Dagnaw/un-pub Overall(I-squared = 98.7%, p = 0.000)	37.00 (32.92, 41.08) 5.01   23.40 (20.22, 26.58) 5.04   40.50 (35.07, 45.93) 4.97   16.70 (12.56, 20.84) 5.01   25.00 (7.01, 27.99) 4.96   38.40 (34.02, 42.78) 5.00   56.60 (51.98, 61.22) 5.00   40.50 (36.21, 44.79) 5.01   40.50 (36.21, 44.79) 5.01   40.50 (36.21, 44.79) 5.01   40.50 (36.21, 44.79) 5.02   40.50 (36.21, 44.79) 5.02   40.50 (36.21, 44.79) 5.02   40.50 (36.21, 44.79) 5.02   40.50 (36.21, 44.79) 5.02   40.50 (36.21, 44.79) 5.02   40.50 (36.21, 44.79) 5.02   40.50 (36.21, 44.79) 5.02   40.50 (36.21, 44.79) 5.02   40.50 (31.71, 44.29) 4.93   16.00 (11.20, 20.80) 4.99   466.00 (61.44, 70.56) 5.00   36.94 (28.55, 45.33) 100.00   40.50 (51.44.70.56) 5.00   36.94 (28.55, 45.33) 100.00

TABLE 2 The overall estimated of discontinuation of long acting reversible contraceptive in Ethiopia, 95% CI, and heterogeneity estimate with a *p*-value for sub-group analysis.

Variables	Characteristics	Pooled estimate of LARCs 95% CI	I <sup>2</sup> ( <i>P</i> -value)
Region	SNNPR	38.020% (25.995–50.045)	98.9% (0.000)
	Amhara	45.036% (26.098-63.975)	98.% (0.000)
	Tigray	36.937% (28.547-45.326)	94.2% (0.000)
	Oromia	30.581% (28.336-52.826)	98% (0.007)
Study setting	Institutional	47.897% (36.365–59.429)	98.7% (0.000)
	Community	25.891% (20.739-31.043)	93.2% (0.000)
Study design	Cross-sectional	37.748% (28.153-47.343)	98.9% (0.000)
	Cohort	32.330(17.731-46.929)	97.3% (0.000)
Cause	Side effect	42.269% (27.869–56.669)	99.3% (0.000)
	Menstrual problem	40.529% (25.345-55.713)	6.8% (0.000)
	Desire for pregnancy	32.812% (21.491-44.132)	94.1% (0.000)
	Health concern	16% (28.547-45.326)	0.000(0.000)
Year of use	Within 1 year	29.518% (21.744-37.292)	97.6% (0.000)
	within 2 year	47.642% (28.547-45.326)	89.9% (0.000)
	Within 3 year	48.885% (39.691-58.079)	99.1% (0.000)

excluding one study at a time. As a result, studies omitted at a time did not show a significant change on the overall prevalence of a discontinuation of long acting contraceptive method (Table 3).

# **Publication bias**

The funnel plot was assessed for asymmetry distribution of discontinuation of long acting reversible contraceptives by

TABLE 3 The pooled prevalence of discontinuation of long acting reversible contraceptives in Ethiopia when one study omitted from the analysis a step at a time 2022.

Study omitted	Pooled estimate	95% CI	
Dagnew et al. (26)	36.934	28.075-45.793	
Nageso and Gebretsadik (27)	37.655	28.888-46.421	
Siyoum et al. (27)	36.751	28.004-45.497	
Wondie et al. (29)	38.004	29.456-46.552	
Melkamu et al. (30)	35.457	27.133-43.780	
Weldekidan et al. (31)	37.691	29.030-46.352	
Gaenamo (32)	36.860	28.034-45.686	
Abebe et al. (23)	35.903	27.299-44.507	
Obsu et al. (33)	36.671	7.911-45.432	
Mesha et al. (34)	37.091	28.282-45.902	
Habte et al. (35)	36.7492	27.919-45.579	
Amare and Reda (36)	36.290	27.587-44.993	
Nega et al. (37)	37.663	28.938-46.388	
Tesfaye et al. (38)	37.869	29.254-46.485	
Geja et al. (39)	37.705	29.005-46.404	
Tolesa et al. (44)	35.182	28.022-42.342	
Abraha et al. (40)	37.928	29.350-46.506	
Gebrekidan et al. (42)	36.882	28.169-45.594	
Birhane (43)	38.036	29.482-46.590	
Yilkal (41)	35.408	27.065-43.751	



visual inspection (Figure 3). The presence of publication bias was also assessed by Egger's regression test *p*-value of 0.875 and Begg's rank correlation test of *p*-value 0.230 with no evidence of publication bias.

# Factors associated with discontinuation of long acting reversible contraceptive methods in Ethiopia

In this study, women experienced side effect of long acting contraceptive methods had higher odds of family planning than their counter parts (AOR = 2.833:95% CI: 2.005–4.003), I<sup>2</sup>: 67.1%, P = 0.000) (Figure 4). In addition, the odds of having discontinuation of long acting contraceptives among mothers who didn't receive counseling on side effects was 2.4 times than their counter parts (AOR = 2.417; 95% CI: 1.591–3.672), I<sup>2</sup>: 69.1%, P = 0.000) (Figure 5).

Women who had no follow up visit after post-insertion of long acting contraception were 2.8 (AOR = 2.820; 95% CI: 2.048–3.881),  $I^2 = 0.0\%$ , P = 0.000) times more likely to discontinue the method than mothers attending follow up visit (Figure 6).

The chance of discontinuation of long acting contraceptive method was 5 times (AOR = 5.156; 95% CI :3.644–7.296),  $I^2 = 0.0\%$ , P = 0.000) among mothers didn't satisfy with services provided than those satisfied by service provision (Figure 7).

Women who had a desire of pregnancy were 2.4 (AOR = 2.366; 95% CI: 1.760–3.182),  $I^2 = 0.0\%$ , P = 0.000) times more likely to discontinue the method than women who had no desire of pregnancy (Figure 8).

#### Discussion

The purpose of this systematic review and meta-analysis was to determine the magnitude of long-acting contraceptive discontinuation and its determinants among Ethiopian women. As a result, the overall prevalence of long-acting contraceptive discontinuation in this study was 36.94 % (95% CI: 28.547–45.326). The current study's findings are higher than those of studies conducted in Malaysia (22.86 %) (45), Nigeria (26.1%) (46), Egypt (26%) (47), a multicenter investigation in nine other countries (20%) (48), and meta-analysis study by Adal (7) (20%). The possible explanation might be due to the difference in the composition of respondents as most of these studies are done by focusing on the rural population and time gap between studies. For example, the above mentioned meta-analysis done by Girum T. includes articles published from 1997 to 2017.

In contrast, the current study's findings are lower than those of research conducted in the Netherlands (47%) (49) and Australia (60%) (50). The time gap between the study and the attention given to the provision of long-acting contraception could be the cause of this discrepancy. This has been supported by the Ethiopian government's adoption of a health extension program to raise awareness and facilitate long-acting contraceptive availability at health post level in the community, which has a favorable impact on discontinuation rates (20, 51).



The association between experiencing side effects and discontinuation of long acting reversible contraception.



Sub-group analysis was done based on study region, setting, design, year of insertion and reason of discontinuation of long acting contraceptive methods. As a result, the Amhara region had a higher rate of contraceptive discontinuation (45%) than the Oromia region (35.6%). This could be due to regional socio-cultural and awareness differences.

The discontinuation rates of institutional-based studies (47.9%) are greater than those of community-based studies (25.9%). It could be because mothers in institutional based research are sufficiently informed of their right to discontinue a method if they get pregnant or unsatisfied with a service.





The pooled prevalence of long-acting contraceptive discontinuation based on study design also showed significant difference, with 37.7% for cross-sectional studies and 32.3% for cohort studies, respectively. Indeed, cross-sectional studies determine prevalence rather than cohort studies, which identify and quantify risks. More evidence is needed, to the best of the researcher's knowledge, to justify this statistical discrepancy.

Side effects were indicated as a significant cause for discontinuing reversible long-acting contraceptives in the current study, which was supported by previous studies

in Port Harcourt (7, 52). This could be due to women's intolerance of modest side effects from reversible long-acting contraceptive methods.

In this study, the proportion of discontinuation rate within the first year of insertion was 29.5 percent, which is higher than studies conducted in 20% of women in Adal (7), Nigeria (8%) (53), Spain (9%) (54), 14 developing countries (13.2%) (55), and Senegal (6.3%) (56). However, this result is lower than that of a research conducted in South Africa (967.3%) (57). The above discrepancy could be attributed to a lack of



effective pre-insertion counseling about predicted side effects, sample size, socio-cultural differences, or the study's time gap. Another explanation could be that most health professionals in our country are reluctant to accept complaints of removal. The findings also revealed that there is no significant change in discontinuation rates between the second (47.6%) and third (48.8%) years of insertion, which is consistent with Bangladesh's (48%) (58).

In our study, women who had long-acting contraceptive side effects were 2.8 times more likely to stop using the method than those who did not (AOR = 2.833:95% CI: 2.005-4.003). This conclusion is supported by research from Kenya (59), Nigeria (60, 61), and Nepal (62). Women's intolerance of minor side effects and vaginal bleeding, which interferes with their sexual experience, could be a viable rationale. Another explanation could be that family planning professionals' lack of ability and experience in dealing with side effects leads to mothers' need to stop using the methods.

Women who were dissatisfied with the services they received were 5 times more likely to discontinue long-acting reversible contraceptives than mothers who were satisfied (AOR = 5.15; 95% CI: 3.644-7.296). This could be attributed to women who were uninterested in method selection, privacy, secrecy, communication competency, and explanation from service providers, all of which have an impact on service continuity.

Women who were not counseled about side effects of long acting reversible contraceptives were 2.4 times more likely to discontinue the method than their counterparts (AOR = 2.417; 95% CI: 1.591-3.672). This is in line with research from Nigeria (53) and Jordan (63). This is due to the fact that mothers who do not receive adequate side effect counseling may develop a

negative attitude toward the method when they experience a side effect.

Women who did not schedule a follow-up appointment were 2.8 times more likely to discontinue than those who did (AOR = 2.820; 95% CI: 2.048–3.881). This is congruent with a study conducted in Port Harcourt (52). This means that during follow-up, women may receive more counseling time from care providers regarding managing side effects and receiving supportive treatment information.

Those who wanted to get pregnant were 2.4 times more likely to stop using long-acting contraceptives than women who didn't (AOR = 2.366; 95% CI: 1.760-3.182). This is consistent with a study done in Nigeria (61). Long-acting contraceptives must be discontinued when clients want to get pregnant (64).

To handle a large variance that occurred in between-study heterogeneity, a random-effect model was used in this research. We conducted leave-one-out sensitivity, and the results reveal that no single study had a substantial effect on the overall prevalence of contraception discontinuation.

We assessed the possible variability source *via* subgroup analysis using the study settings, regions, study design, cause of discontinuation, and year of insertion. The high heterogeneity might be due to differences in the sample populations, paper qualities, or socio-cultural, ethnic, and regional differences.

# Conclusion

In conclusion, the overall prevalence of long-acting contraceptive discontinuation in Ethiopia was high (36.9%).

Furthermore, the pooled discontinuation rate differed by research region, setting, reason, design, and insertion year. Experienced side effects, not being advised about side effects, dissatisfaction with the provided service, no follow-up after insertion, and a desire to become pregnant were all variables that contributed to the discontinuation of long-acting reversible contraceptives, as per this study. The Amhara region of Ethiopia had the highest percentage of discontinuation. It is advisable to address discontinuation by recognizing the significance of side effects in counseling sessions, pregnancy intention, considering the sustainability of currently used contraceptives in view of Ethiopian women's philosophy, and effectively managing and counseling of side effects.

#### Strength and limitation

This study has some limitations. First, there was no adequate similar study to compare the findings of the study. Second, articles were restricted to only being published in the English language and placed in Ethiopia. Third, some of the included studies were cross-sectional, which might affect the outcome variable because of other confounding factors. This research has also some strength. First, compressive electronic online international searching engines were used. Second, our review incorporated gray literature as part of the primary studies.

Third, discontinued long acting contraceptive predictors were discovered.

#### Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author/s.

## References

1. Crespi S, Hanisch M. Implanon (etonogestrel implant) application for WHO EML. Geneva: WHO (2014).

2. Rowlands S, Searle S. Contraceptive implants: current perspectives. *Open Access J Contr.* (2014) 5:73–84. doi: 10.2147/OAJC.S55968

3. Starbird E, Norton M, Marcus R. Investing in family planning: key to achieving the sustainable development goals. *Global Health Sci Prac.* (2016) 4:191–210. doi: 10.9745/GHSP-D-15-00374

4. Caetano C, Bliekendaal S, Engler Y, Lombardo M. From awareness to usage of long-acting reversible contraceptives: Results of a large European survey. *Int J Gynecol Obst.* (2020) 151:366–76. doi: 10.1002/ijgo.13363

5. Secura G. Long-acting reversible contraception: a practical solution to reduce unintended pregnancy. *Minerva Ginecol.* (2013) 65:271–7.

 Adedini SA, Omisakin OA. Somefun OD. Trends, patterns and determinants of long-acting reversible methods of contraception among women in sub-Saharan Africa. PLoS ONE. (2019) 14:e0217574. doi: 10.1371/journal.pone.0217574

#### Author contributions

NG conceptualized the study. NG, KT, and BA contributed during data extraction and analysis. NG, GB, and AY wrote result interpretation. NG and KT prepared the first draft. NG, KT, DS, and BA contributed during the conceptualization, interpretation of results, and substantial revision. NG, KT, DS, GB, BA, and AY revised and finalized the final draft manuscript. All the authors read and approved the final version of the manuscript.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

#### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

### Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh. 2022.979231/full#supplementary-material

9. Curtis S, Evens E, Sambisa W. Contraceptive Discontinuation and Unintended Pregnancy: An Imperfect Relationship. (2017). Available online at: http://citeseerxist.psu.edu/viewdoc/download? (accessed September 15, 2017).

10. Ali MM, Cleland JG, Shah IH. Causes and consequences of contraceptive discontinuation: evidence from 60 demographic and health surveys. *World Health Organ.* (2012) 978:4.

11. Jain AK, Winfrey W. Contribution of contraceptive discontinuation to unintended births in 36 developing countries. *Stud Fam Plann.* (2017) 48:269–78. doi: 10.1111/sifp.12023

<sup>7.</sup> Adal TG. Early discontinuation of long-acting reversible contraceptives among married and in union women: a systematic review and meta-analysis. *Ann Med Health Sci Res.* (2017) 7:6.

<sup>8.</sup> Castle S, Askew I. Contraceptive discontinuation: reasons, challenges, and solutions. solutions. (2015). Available online at: http://www.familyplanning2020org/resources/12011 (accessed December 8, 2015).

12. Jain A. The leaking bucket phenomenon in family planning. Champions for Choice, 1-7. (2014). Available online at: http://champions4choice.org/2014/09/the-leaking-bucket-phenomenon-in-family-planning/#more-1429 (accessed September 9, 2014).

13. Kesetebirhan A. *National Guideline for Family Planning Services in Ethiopia*. Ethiopia: Federal Democratic Republic. (2011).

14. Garbers S, Haines-Stephan J, Lipton Y, Meserve A, Spieler L, Chiasson MA. Continuation of copper-containing intrauterine devices at 6 months. *Contraception.* (2013) 87:101–6. doi: 10.1016/j.contraception.2012.09.013

15. Staveteig S, Mallick L, Winter R. Uptake and discontinuation of longacting reversible contraceptives (LARCs) in low-income countries. *DHS Anal Stud.* (2015) 54:61.

16. Fekadu GA, Omigbodun AO, Roberts OA, Yalew AW. Factors associated with early long-acting reversible contraceptives discontinuation in Ethiopia: evidence from the 2016 Ethiopian demographic and health survey. *Archives Pub Health.* (2020) 78:1–10. doi: 10.1186/s13690-020-00419-w

17. Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. *Stud Fam Plan.* (2014) 45:301–14 doi: 10.1111/j.1728-4465.2014.00393.x

18. Bongaarts J, Cleland JC, Townsend J, Bertrand JT, Gupta MD. Family Planning Programs for the 21st Century: Rationale and Design. New York, NY: Population Council (2012).

19. Central Statistical Authority (CSA) and ORC Macro. *Ethiopia Demographic and Health Survey 2015*. Calverton, MD, USA: CSA and ORC Macro. (2016).

20. Tilahun Y, Asnake M, Ayalew D. *Task Shifting in the Delivery of Long Acting Family Planning Services at Community Level in Ethiopia*. Addis Ababa: Pathfinder International Ethiopia (2011).

21. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med.* (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097

22. Seninde J. Factors Associated with Contraceptive Discontinuation among Women (15-49 Years) In Uganda. (Doctoral dissertation, Makerere University) (2019)

23. Abebe BA, Assefa N, Mengistie B. Discontinuation of reversible long-acting contraceptive and associated factors among female users in health facilities of Hawassa City, Southern Ethiopia: cross-sectional study. *Open Access J Contr.* (2020) 11:113. doi: 10.2147/OAJC.8259978

24. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. *Checklist for Analytical Cross-Sectional Studies*. Adelaide: Joanna Briggs Institute Reviewer's Manual (2017).

25. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of inter-rater agreement. *J Clin Epidemiol.* (2012) 65:934–9 doi: 10.1016/j.jclinepi.2011.11.014

26. Dagnew GW, Gelaw YM, Asresie MB, Anteneh ZA. Level and timing of implanon discontinuation and associated factors among women who used implanon in Andabet district, public health facilities, north-west Ethiopia. *Biomed Res Int.* (2021) 7:6647660. doi: 10.21203/rs.2.12467/v2

27. Nageso A, Gebretsadik A. Discontinuation rate of Implanon and its associated factors among women who ever used Implanon in Dale District, Southern Ethiopia. *BMC Women's Health*. (2018) 18:189. doi: 10.1186/s12905-018-0678-x

28. Siyoum M, Mulaw Z, Abuhay M, Kebebe H. Implanon Discontinuation Rate and Associated Factors among Women who ever Used Implanon in the Last Three Years in Debre Markos Town, Northwest Ethiopia, 2016, Cross Sectional Study. *ARC J Pub Health Commun Med.* (2017) 2:8–16. doi: 10.20431/2456-0596.020 1003

29. Wondie AG. Implanon discontinuation rate and it's associated factors in Debre Tabor Town, North Central Ethiopia. *Sci J Clin Med.* (2019) 8:6-12. doi: 10.11648/j.sjcm.20190802.11

30. Melkamu Asaye M, Syoum Nigussie T, Mequannt Ambaw W. Early implanon discontinuation and associated factors among implanon user women in Debre Tabor Town, public health facilities, Northwest Ethiopia, 2016. *Int J Rep Med.* (2018) 10:3597487. doi: 10.1155/2018/3597487

31. Weldekidan HA, Lemlem SB, Sinishaw Abebe W, Sori SA. Discontinuation rate of long acting Reversible contraceptives and factors Associated among reproductive age women in Butajira town, southern Ethiopia, 2020. *Women Health.* (2020) 18:17455057221104656. doi: 10.1177/17455057221104656

32. Gaenamo AA, Abebe DN. Time to discontinuation of long acting reversible contraceptive methods among married reproductive age women in Hadiya Zone. *J Public Health Policy Plann.* (2022) 6:101. doi: 10.35841/aaphpp-6.1.101

33. Obsu M, Hundessa B, Garoma S, Aman H, Merga H. Magnitude and associated factors of early Implanon discontinuation among rural women in public health facilities of central Ethiopia: a community-based cross-sectional study. *BMC Women's Health.* (2022) 22:72. doi: 10.1186/s12905-022-01651-y

34. Mesha M, Alemayehu A, Daka D. Prevalence and factors associated with early discontinuation rate of Implanon utilization among women who ever used Implanon in Kucha District Gamo Gofa Zone, Southern Ethiopia. *BMC Women's Health.* (2020) 20:239. doi: 10.1186/s12905-020-01096-1

35. Habte A, Wondimu M, Abdulkadir H. Survival time to Implanon discontinuation and its predictors among a cohort of Implanon users who enrolled in public hospitals of southern Ethiopia, 2021: a retrospective cohort study. *Arch Pub Health.* (2022) 80:89. doi: 10.1186/s13690-022-00859-6

36. Amare A, Reda T. Discontinuation of implants use and associated factors among women attending health facility clinics in Hawassa City, Southern Ethiopia, 2019; cross-sectional study. *Contr Rep Med.* (2020) 5:29. doi:10.1186/s40834-020-00128-343

37. Nega G, Abera M, Tadele A. Discontinuation rate and associated factors among contraceptive implant users in Kersa district, southwestern Ethiopia. *Arch Pub Health*. (2021) 79:75. doi: 10.1186/s13690-021-00603-6

38. Tesfaye H, Negara E, Bayisa K. Early implanon discontinuation and associated factors among women ever used implanon in Mettu district, Oromia regional state, southwest Ethiopia, 2021. *Reprod Health.* (2021) 18:176. doi: 10.1186/s12978-021-01222-8

39. Geja E, Belayneh F, Legesse D, Tsegaw D, Abuka T, Gebremariam A. Prevalence of early removal of long-acting contraceptive methods and its associated factors in Sidama regional state, Ethiopia. *Open Access J Cont.* (2021) 12:35–44. doi: 10.2147/OAJC.S280405

40. Abraha HE, Gezae KE, Kahsay AB, Tequare MH. Incidence and predictors of first-year unplanned discontinuation of Implanon at Ayder comprehensive specialized hospital, northern Ethiopia: a retrospective follow-up study. *PLoS ONE.* (2022) 17:e0259234. doi: 10.1371/journal.pone.0259234

41. Melesse YD, Zegeye AM, Kebede GD, Tarik YD, Fenta SL, Getu AA, et al. Discontinuation of Long-Acting Reversible Contraceptive methods and associated factors among women in health facilities of Bahir Dar city, Northwest Ethiopia: A Cross-sectional study. doi: 10.21203/rs.3.rs-1212900/v1

42. Gebrekidan KG, Nerea MK, Gerezgiher H, Haftu M. Early Implanon discontinuation rate and its associated factors in health institutions of Mekelle City, Tigray, Ethiopia 2016/17. *BMC Res Notes.* (2019) 12:8. doi: 10.1186/s13104-018-3992-3

43. Birhane KA, Hagos SE, Fantahun M. Early discontinuation of implanon and its associated factors among women who ever used implanon in Ofla District, Tigray, Northern Ethiopia. *IJPSR*. (2015) 6:554–1.

44. Tolesa B, Alem G, Papelon T. Factors associated with contraceptive discontinuation in Agarfa district, Bale Zone, south east Ethiopia. *Epidemiology.* (2015) 5:1. doi: 10.4172/2161-1165.1000179

45. Mastor A, Khaing SL, Omar SZ. Users' perspectives on Implanon in Malaysia, a multicultural Asian country. *Open Access J Cont.* (2011) 2:79–84. doi: 10.2147/OAJC.S9674

46. Balogun O, Olaomo N, Adeniran A, Fawole A. Implanon sub-dermal implant: an emerging method of contraception in Ilorin, Nigeria. *J Med Biomed Sci.* (2014) 3:1–5. doi: 10.4314/jmbs.v3i1.1

47. Said MA-RM, Cairo U. Implanon Use Pattern Among Ministry of Health and Population Clients 2008–2012. Cairo: Faculty of Medicine (2012).

48. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. *Obstet Gynecol.* (2011) 117:1105–1113. doi: 10.1097/AOG.0b013e31821188ad

49. Teunissen AM, Grimm B, Roumen FJ. Continuation rates of the subdermal contraceptive Implanon<sup>®</sup> and associated influencing factors. *Eur J Contracept Reprod Health Care.* (2014) 19:15–21. doi: 10.3109/13625187.2013.862231

50. Harvey C, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon<sup>®</sup> users accessing two family planning clinics in Queensland, Australia. *Contraception.* (2009) 80:527–32. doi: 10.1016/j.contraception.2009.05.132

51. Hubacher D, Dorflinger L. Avoiding controversy in international provision of subdermal contraceptive implants. *Contraception*. (2012) 85:432–3. doi: 10.1016/j.contraception.2011.11.018

52. Ojule JD. Implanon implant contraception at the university of Port Harcourt teaching hospital. *Asian J Med Health.* (2018) 11:1-6 doi: 10.9734/AJMAH/2018/40017

53. Ezegwui H, Ikeako L, Ishiekwene C, Oguanua T. The discontinuation rate and reasons for discontinuation of implanon at the family planning clinic of University of Nigeria Teaching Hospital (UNTH) Enugu, Nigeria. *Niger J Med.* (2011) 20:448–50. 54. Arribas-Mir L, Rueda-Lozano D, Agrela-Cardona M. Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain. *Contraception.* (2009) 80:457–62. doi: 10.1016/j.contraception.2009.04.003

55. Ali, Mohamed M, Sadler Rachael K, Cleland John, Ngo Thoai D, Shah Iqbal H. Long Term Contraceptive Protection, Discontinuation and Switching Behaviour: Intrauterine Device (IUD) Use Dynamics in 14 Developing Countries. London: World Health Organization and Marie Stopes International (2011).

56. Barden-O'Fallon J, Speizer IS, Calhoun LM, Corroon M. Women's Contraceptive discontinuation and switching behavior in urban Senegal, 2010–2015. *BioMed Central.* (2018) 18:1–5. doi: 10.1186/s12905-018-0529-9

57. Mrwebi KP, Goon DT, Owolabi EO, Adeniyi OV, Seekoe E, Ajayi AI. Reasons for discontinuation of Implanon among users in buffalo city metropolitan municipality, South Africa: a cross-sectional study. *Afr J Reprod Health*. (2018) 22:113–9. doi: 10.29063/ajrh2018/v22i1.1159

58. Mahboob El-Alam, Searing H, Bradley J, Shabnam F. *IUD Use and Discontinuation in Bangladesh*. New York, NY: The Acquire Project (2010).

59. Maina SW, Sanjo GO, Dwigah SN. Determinants of discontinuation of contraceptive methods among women at Kenyatta National Hospital, Kenya. *Afr J Pharmacol Ther.* (2016) 5:283

60. Igwe N. Intrauterine contraceptive device use in Abakaliki, Southeast Nigeria: a 5-year review. *Trop J Med Res.* (2016) 19:138. doi: 10.4103/1119-0388.185441

61. Muthir J, Nyango D. Indications for removal of Etonogestrel implant within two years of use in Jos, Nigeria. *East Afr Med J.* (2010) 87:11.

62. Thapa S. Early discontinuation of intrauterine device in Nepal-a retrospective study. WHO South-East Asia J Public Health. (2012) 1:309-19. doi: 10.4103/2224-3151.207027

63. Kamhawi C, Underwood H, Jabre B. Clientcentered counseling improves client satisfaction with family planning visits: evidence from Irbid, Jordan. *Global Health: Sci Prac J.* (2013) 1:180–92. doi: 10.9745/GHSP-D-12-00051

64. Weldemariam KT, Gezae KE, Abebe HT. Reasons and multilevel factors associated with unscheduled contraceptive use discontinuation in Ethiopia: evidence from Ethiopian demographic and health survey 2016. *BMC Public Health.* (2019) 19:1–15. doi: 10.1186/s12889-019-8088-z